SES CEO Adel Al-Saleh said the third quarter of 2025 marked the first quarter of the combined company following the...
financial
Altimmune, Inc 48-week Data from Phase 2b IMPACT Trial of Pemvidutide in MASH Expected Before Year End End-of-Phase 2 Meeting...
Behind any good small business retirement plan health is good small plan sponsor health, according to a recent study by...
Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI’s unprecedented...
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Resolute Holdings Management, Inc. (“Resolute Holdings”) (NYSE: RHLD), an operating management company...
Syndax Pharmaceuticals, Inc. – $45.9 million in total revenue, representing 21% growth over 2Q25 – – $32.0 million Revuforj® (revumenib)...
